Use of idarucizumab in clinical practice: a case report


Authors: Libuše Husová
Authors‘ workplace: Centrum kardiovaskulární a transplantační chirurgie, Brno
Published in: Vnitř Lék 2019; 65(5): 377-378
Category: Case reports

Overview

Budd-Chiari syndrome is a serious condition which in chronic course leads to the development of liver cirrhosis. Anti­coagulant treatment of this syndrome is fully indicated and in the treatment can be used dabigatran. Advanced cirrhosis of the liver due to this disease can be an indication for a liver transplant. In this case, it is a great advantage the existence of an antidote to dabigatran (idarucizumab) in order to adjust the coagulation ratios and prevent bleeding disorders. Referred to a case report describes the first experience with idarucizumab in context with liver transplant in a patient with Budd-Chiari syndrome

Keywords:

antidote – bleeding – dabigatran – direct oral anticoagulants (DOAC) – idarucizumab – liver transplant


Sources
  1. Šembera Š, Hůlek P. Onemocnění jaterních cév. In: Hůlek P, Urbánek P et al. Hepatologie. 3. vydání. Grada: Praha 2018. ISBN 437–451.978–80–271–0394–2.
  2. Warfarin. Souhrn údajů o přípravku. Informace z WWW: http://www.sukl.cz.
  3. Kvasnička J, Penka M, Kvasnička T et al. Doporučení České společnosti pro trombózu a hemostázu J. E. Purkyně pro bezpečnou léčbu novými antikoagulancii (NOAC) – dabigatran etexilátem, apixabanem a rivaroxabanem. Vnitř Lék 2015; 61(6): 537–546.
  4. Pradaxa. Souhrn údajů o přípravku. Informace z WWW: http://www.sukl.cz.
  5. Pollack CV, Reilly PA, Eikelboom J et al. Idarucizumab for Dabigatran Reversal. N Engl J Med 2015; 373(6): 511–520. Dostupné z DOI: <http://dx.doi.org/10.1056/NEJMoa1502000>.
Labels
Diabetology Endocrinology Internal medicine
Login
Forgotten password

Don‘t have an account?  Create new account

Forgotten password

Enter the email address that you registered with. We will send you instructions on how to set a new password.

Login

Don‘t have an account?  Create new account

×